IMMUTEP LIMITED — AGM Information 2021

Jul 25, 2021

==> picture [37 x 37] intentionally omitted <==

The global leader in developing LAG-3 therapeutics (ASX: IMM, NASDAQ: IMMP) Extraordinary General Meeting CEO Presentation 26 July 2021

Notice: Forward Looking Statements

==> picture [170 x 60] intentionally omitted <==

The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Immutep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company’s filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward-looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immutep’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immutep’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Immutep. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This presentation is authorised for release by Marc Voigt, CEO of Immutep Limited.

2

Overview

==> picture [170 x 60] intentionally omitted <==

Immutep

is an innovative biotechnology company developing novel immunotherapies for cancer and autoimmune disease

Collaboration deals executed with industry leaders

==> picture [94 x 21] intentionally omitted <==

==> picture [48 x 30] intentionally omitted <==

==> picture [94 x 34] intentionally omitted <==

==> picture [83 x 34] intentionally omitted <==

==> picture [119 x 46] intentionally omitted <==

==> picture [59 x 18] intentionally omitted <==

==> picture [76 x 24] intentionally omitted <==

==> picture [80 x 17] intentionally omitted <==

Global leadership position

in LAG-3 with 4 product candidates in immuno-oncology and autoimmune disease

Clinical Potential

Immutep’s product candidates have demonstrated clinical potential in a range of indications with high unmet need

3

==> picture [169 x 59] intentionally omitted <==

LAG-3 Overview - Landscape-

LAG-3 Acceleration & Validation

==> picture [170 x 60] intentionally omitted <==

LAG-3 Scientific Publications

LAG-3 is an exciting and promising immune checkpoint for cancer treatment

Accelerating interest in LAG-3:

• Over 900 scientific publications dealing with LAG-3

• More than 80 clinical trials evaluating 19 LAG-3 product candidates in development

• Close to 20,000 patients estimated to be enrolled in clinical trials around the globe

Recent LAG-3 validation:

• Interaction between LAG-3 and MHC class II was recently validated by pharma company Bristol Myers Squibb with Phase III data

• Its anti-LAG-3 antibody is helping patients with melanoma to live significantly longer without disease progression (PFS)

Immutep is the leading LAG-3 immunotherapy biotech It is the only company with four LAG-3 related compounds each with a different mechanism of action.

==> picture [308 x 196] intentionally omitted <==

==> picture [75 x 8] intentionally omitted <==

----- Start of picture text -----

Source: PubMed
----- End of picture text -----

LAG-3 Clinical Trials

==> picture [308 x 172] intentionally omitted <==

Source: GlobalData, May 2021

5

Immutep’s LAG-3 Trial Pipeline*

==> picture [170 x 60] intentionally omitted <==

Oncology Autoimm. Inf. Dis.	Program	Preclinical	Phase I	Phase II	Late Stage(5)	Commercial Rights	Market Size(6)
	Eftilagimod Alpha (efti or IMP321) APC activating soluble LAG-3 protein	Metastatic Breast Cancer (C AIPAC	hemo – IO)			Global Rights	US$29.9 billion
		Head and Neck Squamous TACTI-003	Cell Carcinoma (IO – IO)(1b)				US$1.9 billion
		Head and Neck Squamous TACTI-002	Cell Carcinoma (IO – IO)(1)
		Non-Small-Cell Lung Carci TACTI-002	noma (IO – IO)(1)				US$22.6 billion
		Solid Tumors (IO – IO)(2), (3 INSIGHT-004	a)
		Solid Tumors (IO – IO)(2), (3 INSIGHT-005	b)		§
		Solid Tumors (IO – IO – ch INSIGHT-003	emo)(2)
		Solid Tumors (Cancer Vacc YNP01 / YCP02 / CRESCE	ine)(4a) NT 1
		Metastatic Breast Cancer (C	hemo – IO)(4b)		§	Chinese Rights	US$2.3 billion
	Efti	COVID-19 disease (Monoth EAT-COVID	erapy)(7)		~~§~~	Global Rights(8)
	IMP761 (Agonist AB)				~~§~~	Global Rights	US$149.4 billion (2025)

Notes

• Information in pipeline chart current as at June 2021

• (1) In combination with KEYTRUDA® (pembrolizumab) (1b) Planned new trial for 1[st] line HNSCC patients

• 6 (2) INSIGHT Investigator Initiated Trial (“IIT”) is controlled by lead investigator and therefore Immutep has no control over this clinical trial

• 6 (3) a) In combination with BAVENCIO® (avelumab); b) in combination with Bintrafusp alfa

• (4) a) Conducted by CYTLIMIC in Japan; b) Conducted by EOC in China. Immutep has no control over either of these trials.

• Late stage refers to Phase IIb clinical trials or more clinically advanced clinical trials GlobalData Market Size forecast for US, JP, EU5, Urban China and Australia; KBV Research: https://www.kbvresearch.com/autoimmune-disease-therapeutics-market/)

• (5)

• (6)

• (7) IIT conducted by University Hospital Pilsen. Immutep has no control over this trial. (8) Ex China

*** Immutep Out-Licensed LAG-3 Trial Pipeline**

==> picture [170 x 60] intentionally omitted <==

Oncology Autoimmune	Program	Preclinical	Phase I	Phase II	Late Stage(1)	Commercial Rights/Partners	Updates
	LAG525 (Antagonist AB)	Solid Tumors + Blood C	ancer (IO-IO Combo)			Global Rights	Novartis currently has five clinical trials ongoing for LAG525 in multiple cancer indications for over 1,000 patients.(4)
		Triple Negative Breast	Cancer (Chemo-IO Comb	o)
		Melanoma (IO-IO-Small	Molecule Combo)		~~§~~
		Solid Tumors (IO-IO Co	mbo)
		Triple Negative Breast (Chemo-IO-Small Molec	Cancer ule Combo)
	GSK‘781 (Depleting AB)	Ulcerative Colitis Ulcerative Colitis(6)				Global Rights	Two successful Phase I studies, but the Phase II clinical study in up to 242 ulcerative colitis patients was discontinued.(5)
		Healthy Japanese and C	aucasian Subjects(2)		§
		Psoriasis(3)

Notes

7 * Information in pipeline chart current as at June 2021 7 (1) Late stage refers to Phase IIb clinical trials or more clinically advanced clinical trials (2) Reflects completed Phase I study in healthy volunteers

(4)

(5)

https://clinicaltrials.gov/ct2/results?cond=&term=LAG525&cntry=&state=&city=&dist= https://clinicaltrials.gov/ct2/results?cond=&term=GSK2831781&cntry=&state=&city=&dist= and https://www.gsk.com/media/5957/q1-2020-results-slides.pdf Discontinued in Jan 2021

TACTI-002 (Phase II)

Design & Status

==> picture [170 x 60] intentionally omitted <==

TACTI-002: Two ACTive Immunotherapeutics in NSCLC and HNSCC

==> picture [530 x 270] intentionally omitted <==

----- Start of picture text -----

UNSELECTED FOR PD-L1
PART A:
S
1 [ST] LINE MET. NSCLC
C
R
PART B: COMBINED
E
2 [ND] LINE MET. NSCLC, IMMUNOTHERAPY
E
PEMBROLIZUMAB + EFTI FOR 12
N REFRACTORY TO PD-1/PD-L1 MONTHS + 12 MONTHS
TARGETING THERAPY PEMBROLIZUMAB MONO
I
N
PART C:
G
2 [ND] LINE MET. HNSCC AFTER Status Report
PLATINUM THERAPY
✓ Fully approved in all countries
----- End of picture text -----

In collaboration with

==> picture [188 x 49] intentionally omitted <==

ORR, PFS, OS, PK, biomarker, safety and tolerability

Sites in Europe / US / Australia

==> picture [224 x 171] intentionally omitted <==

• ✓ Up to 183 patients in three indications

30 mg efti (IMP321) s.c. Treatment 200 mg pembrolizumab (Keytruda[] ) i.v.

• Part A (N=36) completed; extension (N=74 recruiting)

• ✓ Part C (N=39) completed

• Part B (N=36); stage 2 recruitment ongoing

Notes:

8

ORR – overall response rate, DCR – disease control rate, PFS – progression free survival, OS – overall survival, QoL – Quality of life

TACTI-002 Results[(1)]

1[st] line NSCLC (Part A)

==> picture [170 x 60] intentionally omitted <==

• PD-L1 distribution as expected (~70% with < 50% PD-L1 expression) → PD L1 all comer trial

• Patients are typical NSCLC 1[st] line pts

Baseline parameters	N (%)
Age (years), median (range)	68.5 (53-84)
Female Male	11 (30.6) 25 (69.4)
ECOG 0 ECOG 1	15 (41.7) 21 (58.3)
Current / Ex-smokers Non-smokers	34 (94.4) 2 (5.6)
Squamous pathology Non-squamous pathology	15 (41.7) 21 (58.3)
Patients with liver metastasis	14 (38.9)

Best overall response, iRECIST, N = 36	Local Read (investigator) N(%)	Blinded Read (BICR) N(%)
Complete Response	2 (5.6)	2 (5.6)
Partial Response	11 (30.6)	13 (36.1)
Stable Disease	11 (30.6)	10 (27.8)
Progression	8 (22.2)	6 (16.7)
Not Evaluable**	4 (11.1)	5 (13.9)
Disease Control Rate	24 (66.7)	25 (69.4)
Overall Response Rate [95% CI interval]*	13 (36.1) [20.8-53.8]	15 (41.7) [25.5-59.2]
Overall Response Rate – Evaluable pts *[95% CI interval]	13 (40.6) [23.7-59.4]	15 (48.4) [30.1-60.9]

• - All patients stage 1 and 2 (N=36) with ≥ 1 treatment

• ** - dropped off prior to first staging or were not evaluable post-baseline for any reason

• *** - Evaluable for efficacy meaning ≥ 1 treatment and ≥ 1 post baseline tumor staging

Notes:

(1) Preliminary data, cut-off Apr 16, 2021 9 ECOG… Eastern Cooperative Oncology Group iRECIST… Immune Response Evaluation Criteria In Solid Tumors BICR… Blinded Independent Central Review

TACTI-002 Results[(1)]

1[st] line NSCLC (Part A)

==> picture [170 x 60] intentionally omitted <==

==> picture [826 x 245] intentionally omitted <==

----- Start of picture text -----

120 Best response:
iUPD/iCPD 100 Best response:
100
iSD iUPD/iCPD
75
60 iSD
iPR
iPR
40 iCR 50
iCR
20
25
0
0
-20
-25
-40
-60 -50
-80
-75
cut-off 16-Apr 2021; n= 33
-100 N=33; ** LN as target lesion; *** - pt had SD but < 6 wks --> BOR =
NE; NY not yet; NE not evaluable
0 12 24 36 48 60 72 84 96 108 120 -100
PD-L1 TPS
% change compared to baseline
Best % change from baseline

50 % 80 % 50 % 15 % 3 % 15 % 80 % 0 % 50 % 70 % 10 % 10 % 10 % 1 % 100 % 0 % 50 % 75 % 90 % 90 % 75 % 100 % 0 %
25 % 0 % 1 % 2 % 40 % <1 % 0 % <1 % 15 % 35 %

----- End of picture text -----

==> picture [230 x 11] intentionally omitted <==

----- Start of picture text -----

weeks … patients still under therapy
----- End of picture text -----

Duration of response (DoR)

• 92% responses confirmed

• 58% confirmed responses ongoing with 6+ months

• 42% of confirmed responses progressed after 6.5-13.8 months

• Responses at all PD-L1 levels including 1 Complete Response with TPS of 0%

• At data cut-off, 7 pts still under therapy and 1 patient completed the 2 years of therapy

• Median DoR estimated 13+ months

(1) Preliminary data, cut-off Apr 16, 2021 Graphs represent all patients with at least one post baseline assessment. One patient has no official RECIST assessment as this was done < 6 weeks and this does not qualify according to RECIST. Per local investigator assessment. iRECIST… Immune Response Evaluation Criteria In Solid Tumors

10

TACTI-002 Results[(1)]

2[nd] line HNSCC (Part C)

==> picture [170 x 60] intentionally omitted <==

• 2[nd] line treatment for patients after platinum therapy. PD-L1 all comer population

• Doubling the ORR compared to historical pembro mono results with 13.5% Complete Responses

Baseline parameters (N=39)	N (%)	Best overall response*, iRECIST	Investigator assessment N (%)
Age, median (years)	62 (37-84)	Complete Response	5 (13.5)
Female Male	4 (10.3) 35 (89.7) 13 (33.3) 26 (66.7) 33 (84.6) 6 (15.4) 39 (100) 16 (41.0) 19 (48.7) 6 (17.6)	Partial Response	6 (16.2)
		Stable Disease	3 (8.1)
ECOG 0 ECOG 1
		Progression	17 (45.9)
		Not Evaluable**	6 (16.2)
Current / Ex-smokers Non-smokers
		Disease Control Rate	14 (37.8)
Previous chemotherapy		Overall Response Rate [95% CI interval]	11 (29.7) [15.9-47.0]
Previous cetuximab
		Overall Response Rate – Evaluable pts *[95% CI interval]	11 (35.5) [19.2-54.6]
Lung lesions Liver lesions

Primary tumor location (N=39)	N (%)
Oral cavity	12 (30.8)
Oropharynx	14 (35.9)
Hypopharynx	7 (17.9)
Larynx	6 (15.4)

• - All patients (N=37) with ≥ 1 treatment and no death due to COVID-19 prior to first post-baseline staging ** - dropped off prior to first staging or were not evaluable post-baseline for any reason

• *** - evaluable patients (N=31): ≥ 1 treatment and ≥ 1 post baseline tumor staging

All four pathologies enrolled

Note:

(1) Preliminary data, cut-off 16 Apr 2021

11

TACTI-002 Results[(1)] 2[nd] line HNSCC (Part C)

==> picture [170 x 60] intentionally omitted <==

==> picture [404 x 230] intentionally omitted <==

----- Start of picture text -----

Best response:
100
iUPD/iCPD
75 iSD
iPR
50
iCR
25
PD-L1 CPS
0
-25
-50
-75
n = 31
-100
- NE - not evaluable; NY - not yet evaluated ** LN as target lesion; *** target
lesion decrease at PD due to NL


8 4 NE NY 1 100 2 7 0 5 5 5 0 7 5 2 5 <5 4 0 4 1 8 5
0 0 0 1 1 1 0 NE 2 8 NY 0 NE 0 4 1 1 NY 0 NY
Best % change from baseline
----- End of picture text -----

==> picture [385 x 269] intentionally omitted <==

----- Start of picture text -----

100
Best response:
80
iUPD/iCPD
60 iSD
iPR
40
iCR
20
0
-20
-40
-60
-80
-100
0 12 24 36 48 60 72 84 96
cut-off 16-Apr 2021, n=31
weeks
… patients still under therapy
% change compared to start of therapy
----- End of picture text -----*

Figure 3: Duration of response (DOR) for confirmed responders

==> picture [222 x 159] intentionally omitted <==

----- Start of picture text -----

100
50
DoR HNSCC
N=10
0
0 6 12 18
months
Probability of Survival
----- End of picture text -----

Deep responses with 5 Complete Responses Duration of response (DoR)

• 91% confirmed responses

• 80% confirmed responses ongoing (censoring at 4-20 months)

• No progression prior to 6 months DOR

• Median duration of response cannot be estimated yet

Note:

(1) Preliminary data, cut-off 16 Apr 2021 ** >= 1 post baseline tumor staging (N=31)

12

TACTI-002 Results[(1)]

2[nd] line HNSCC (Part C)

==> picture [170 x 60] intentionally omitted <==

Kaplan-Meier Plot PFS*

==> picture [381 x 240] intentionally omitted <==

----- Start of picture text -----

100
90
CPS >=1 (n=24)
80
unselected for PD-L1 (n=37)
70
60
50
40
30
20
10
0
0 6 12 18 24
Probability of Survival
----- End of picture text -----

months

Overall population (unselected for PD-L1)

Selected for PD-L1 expression, CPS ≥ 1 *

• Median PFS 2.1 mths

• 30+% progression free at 6 mths

Median OS (58% events) 12.6 mths Median PFS (71% events) 4.1 mths (45% prog. free at 6 mths) ORR iRECIST (95% CI) 45.8% (25.6-67.2)

Note:

(1) Preliminary data, cut-off 16 Apr 2021 (2) * ≥ 1 treatment and no death due to COVID-19 prior to first post-baseline staging (N=37)

13

INSIGHT-004 (Stratum D) Results[(1)]

==> picture [170 x 60] intentionally omitted <==

Efficacy

• 5/12 (42%) with partial responses in different indications:

• 1st line MSI high colorectal cancer; 1st line pleural mesothelioma; after radiochemo in squamous anal cell; pre-treated squamous cervical cancer (PD-L1 TPS < 1%) carcinoma; 3[rd] line gastroesophageal junction

• 75% (n=9) are still alive → 66.7% (n=4) of cohort 1 and 83.3% (n=5) of cohort 2

Safety

• Combo of avelumab 800 mg + efti 6 mg or 30 mg efti s.c. is feasible and safe

• No unexpected AEs

Conclusion

• Treatment with efti + avelumab safe, with promising signals of efficacy

• Efti + avelumab seems to be a potent combination for enhancing PD-L1 directed therapy and needs further evaluation in new trials

==> picture [360 x 453] intentionally omitted <==

----- Start of picture text -----

Best overall response (RECIST 1.1)
----- End of picture text -----

Note:

14

(1) ASCO 2021: J Clin Oncol 39, 2021 (suppl 15; abstr 2518); DOI 10.1200/JCO.2021.39.15_suppl.2518

IMP761 a Potential Game Changer for Autoimmune Diseases

Current autoimmune drugs fight the symptoms, treating general inflammation (corticoids, methotrexate, anti-TNF-α, -IL-6, -IL-17, - IL-23 mAbs)

IMP761 potentially fights the cause, treating the disease process by silencing the few autoimmune memory T cells accumulating at the disease site

Immutep to submit an Investigational New Drug (IND) application with the US FDA to begin clinical trials

==> picture [308 x 137] intentionally omitted <==

US$153.32 billion market by 2025[1]

==> picture [170 x 60] intentionally omitted <==

==> picture [285 x 399] intentionally omitted <==

IMP761 has broad potential in targeting auto-reactive memory T cells

15 Notes 15 (1) Source: https://www.researchandmarkets.com/reports/4828880/autoimmune-disease-therapeuticsmarket-by-drug

==> picture [169 x 59] intentionally omitted <==

New Efti Studies - TACTI-003, INSIGHT-005 & INSIGHT-003 -

Positive data driving expansion of clinical program

==> picture [170 x 60] intentionally omitted <==

With the ongoing strength of data reported at leading conferences SITC 2020; SABCS 2020; ASCO 2021), : Immutep plans to expand and advance its clinical portfolio[(1)]

==> picture [763 x 233] intentionally omitted <==

----- Start of picture text -----

Manufacturing
New Phase III Registration Other Trials
New Phase II Trial
Trial Commence process
Two new investigator-
e.g. Triple therapy: anti-PD1 characterisation and
Metastatic breast cancer initiated trials (IITs) with up
+ chemo + efti combination validation for efti commercial
(based on AIPAC) to 40 pts each
manufacturing (2,000 L scale)
Regulatory
Autoimmune Program Strengthen the team
Ongoing interactions with
IND package for IMP761 and research projects
the FDA and EMA
----- End of picture text -----

Immutep expects a range of clinical trials to have significant data read outs in the coming years

17 Notes 17 (1) Expansion and advancement of clinical portfolio is subject to achieving relevant regulatory approvals.

TACTI-003 Trial in 1[st] line HNSCC

Current Design + Status

==> picture [530 x 452] intentionally omitted <==

==> picture [170 x 60] intentionally omitted <==

In collaboration with

==> picture [213 x 56] intentionally omitted <==

Design:

• Randomised study with ORR as primary endpoint

• Sites worldwide (AU, US, Europe)

• Approx. 154 pts: either to be randomized to have sufficient pts. in each group or in an experimental arm

Status:

• Study start up announced on 6 July 2021, with patient recruitment expected to begin within Q3 of calendar year 2021.

• Fast Track designation granted by FDA in April 2021

18

INSIGHT Platform Trial in Solid Tumours

INSIGHT-005 study arm (Stratum E): Efti + Bintrafusp Alfa combo

==> picture [170 x 60] intentionally omitted <==

To evaluate the feasibility and safety of combined treatment with bintrafusp alfa (M7824) and eftilagimod alpha.

In collaboration with:

==> picture [100 x 42] intentionally omitted <==

==> picture [42 x 36] intentionally omitted <==

Institut für Klinisch-Onkologische Forschung

==> picture [148 x 117] intentionally omitted <==

Bintrafusp alfa: bifunctional fusion protein that aims to block two immunosuppressive pathways: TGF-β and PD-L1

==> picture [41 x 42] intentionally omitted <==

Phase I/IIa 12 Open label trial Patients in 3 cohorts

==> picture [70 x 68] intentionally omitted <==

Efti: LAG-3 fusion protein that activates antigen presenting cells (APCs) via the LAG-3 – MHC II pathway

==> picture [41 x 41] intentionally omitted <==

12 months Combination treatment

==> picture [41 x 41] intentionally omitted <==

Two sites Germany

Solid tumors

• histologically confirmed locally advanced or metastatic

• received ≤ 4 prior lines of therapy

Q2W for maximum of 12 months

• bintrafusp alfa 1200 mg i.v.

• eftilagimod alpha 30 mg s.c.

RP2D, Safety, ORR, PFS, PK, PD

19

INSIGHT Platform Trial in Solid Tumours

New INSIGHT-003 study arm (Stratum C): Efti + anti-PD-1 + chemo

==> picture [170 x 60] intentionally omitted <==

First evaluation of efti in a triple combination therapy

INSIGHT-003 is a new stratum of the investigator-initiated phase I trial, INSIGHT

• Expansion into triple combination therapy of efti, standard of care chemotherapy and anti-PD-1 therapy

• Regulatory and ethical approvals received enabling patient recruitment

• First patient expected to be enrolled in Q3 of calendar year 2021 and first interim results expected in 2022

• Results to inform about safety and activity

==> picture [60 x 113] intentionally omitted <==

==> picture [60 x 48] intentionally omitted <==

==> picture [60 x 48] intentionally omitted <==

==> picture [60 x 48] intentionally omitted <==

Phase I study

Up to 20 patients with various solid tumours

Safety, tolerability & initial activity

One site

Germany

24 weeks

therapy duration

20 20

==> picture [169 x 59] intentionally omitted <==

Corporate Snapshot & Outlook

Corporate Snapshot

==> picture [170 x 60] intentionally omitted <==

==> picture [668 x 314] intentionally omitted <==

----- Start of picture text -----

IMM (ASX)
Ticker symbols
IMMP (NASDAQ)
Securities on issue [(1)]
~ 850.92 million ordinary shares
(post transaction)
Proforma cash balance [(2)]
~ A$114.03 million (US$85.73 million)
(post transaction)
Market Cap [(3)]
~ A$425.46 million (US$311.61 million)
(post transaction)
----- End of picture text -----

Notes:

NB: All above figures are provided on a “post transaction” basis and include new Shares from the completed Share Purchase Plan (SPP) (the details of which were announced to ASX on 21 July 2021) and assumes Tranche 2 Placement Shares are approved by shareholders at today’s EGM.

• (1) As at 30 Jun 2021, 39.04% of the ordinary shares are represented by ADSs listed on NASDAQ where 1 ADS represents 10 ordinary shares.

• (2) Pro forma cash balance based on Immutep’s cash balance at 30 June 2021 plus the gross proceeds from the SPP and Tranche 2 share issuance.

• (3) Market capitalization based on ASX close share price of A$0.50 on 21 July 2021 and basic ordinary shares outstanding on a post transaction basis.

US equivalent of amounts above are based on foreign exchange rate for AUD/USD of 0.7324 for market capitalization, and the US cash & cash equivalents amount was calculated using FX rate of 0.7518.

22

2021/2022 News Flow*

==> picture [170 x 60] intentionally omitted <==

==> picture [806 x 53] intentionally omitted <==

----- Start of picture text -----

H1 2021 H2 2021 2022
----- End of picture text -----

• ✓ Fast Track designation granted for efti in 1[st] line HNSCC from US FDA

• ✓ Data from TACTI-002 & final data from INSIGHT004 at ASCO

• ✓ Expansion of existing programs, adding:

• ✓ Second collaboration with MSD for TACTI-003

• ✓ First triple combination therapy with efti in INSIGHT-003

• ✓ New collaboration with Merck KGaA for INSIGHT-005

• ✓ Patent protection strengthened

• ✓ Financial position significantly strengthened

• ✓ Validation of LAG-3/MHC-II interaction through BMS’s Phase III results in melanoma

• ❑ Final data from AIPAC : 2[nd] OS follow up in H2 2021

• ❑ Start & ongoing recruitment of new randomised trial in 1st line HNSCC (TACTI-003) in Q3 2021

• ❑ Recruitment & further data from TACTI-002 in 2021 or early 2022

• ❑ INSIGHT-003 first patient enrolled in Q3 2021 and first interim results in 2022

• ❑ INSIGHT-005 first patient enrolled in H2 2021

• ❑ Manufacturing scale up to 2,000 L

• ❑ Ongoing regulatory engagement

• ❑ Updates from IMP761

• ❑ Updates from partnered programs (e.g. GSK, Novartis, EAT COVID, CYTLIMIC and EOC Pharma)

Notes:

*The actual timing of future data readouts may differ from expected timing shown above. These dates are provided on a calendar year basis. A tick symbol indicates a completed item.

23

==> picture [67 x 105] intentionally omitted <==

Thank You